Self-assembled Hybrid Nanoparticles for Targeted Co-delivery of Two Drugs into Cancer Cells

Overview

Journal Chem Commun (Camb)

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2014 Feb 12

PMID 24516863

Citations 29

Authors

Fujian Huang

Mingxu You

Tao Chen

Guizhi Zhu

Haojun Liang

Weihong Tan

Affiliations

Soon will be listed here.

Abstract

A therapeutic aptamer-lipid-poly(lactide-co-glycolic acid) hybrid nanoparticle-based drug delivery system was prepared and characterized. This system can co-deliver two different drugs with distinct solubility and different anticancer mechanisms to target cancer cells with high specificity and efficiency.

Citing Articles

Aptamer-Based Targeting of Cancer: A Powerful Tool for Diagnostic and Therapeutic Aims.

Mohammadinejad A, Gaman L, Aleyaghoob G, Gaceu L, Mohajeri S, Moga M Biosensors (Basel). 2024; 14(2).

PMID: 38391997 PMC: 10887380. DOI: 10.3390/bios14020078.

Structure and dynamics of an archetypal DNA nanoarchitecture revealed via cryo-EM and molecular dynamics simulations.

Ahmad K, Javed A, Lanphere C, Coveney P, Orlova E, Howorka S Nat Commun. 2023; 14(1):3630.

PMID: 37336895 PMC: 10279742. DOI: 10.1038/s41467-023-38681-5.

Aptamer nucleotide analog drug conjugates in the targeting therapy of cancers.

Li Y, Zhao J, Xue Z, Tsang C, Qiao X, Dong L Front Cell Dev Biol. 2022; 10:1053984.

PMID: 36544906 PMC: 9760908. DOI: 10.3389/fcell.2022.1053984.

Insights on the Dynamic Innovative Tumor Targeted-Nanoparticles-Based Drug Delivery Systems Activation Techniques.

Hamdy N, Eskander G, Basalious E Int J Nanomedicine. 2022; 17:6131-6155.

PMID: 36514378 PMC: 9741821. DOI: 10.2147/IJN.S386037.

Recent advances in surface modification of micro- and nano-scale biomaterials with biological membranes and biomolecules.

Abesekara M, Chau Y Front Bioeng Biotechnol. 2022; 10:972790.

PMID: 36312538 PMC: 9597319. DOI: 10.3389/fbioe.2022.972790.

References

Costantino L, Gandolfi F, Tosi G, Rivasi F, Vandelli M, Forni F . Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. J Control Release. 2005; 108(1):84-96. DOI: 10.1016/j.jconrel.2005.07.013. View

Wang H, Zhao Y, Wu Y, Hu Y, Nan K, Nie G . Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials. 2011; 32(32):8281-90. DOI: 10.1016/j.biomaterials.2011.07.032. View

Bagalkot V, Farokhzad O, Langer R, Jon S . An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed Engl. 2006; 45(48):8149-52. DOI: 10.1002/anie.200602251. View

Davis M, Chen Z, Shin D . Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008; 7(9):771-82. DOI: 10.1038/nrd2614. View

Zhu G, Zheng J, Song E, Donovan M, Zhang K, Liu C . Self-assembled, aptamer-tethered DNA nanotrains for targeted transport of molecular drugs in cancer theranostics. Proc Natl Acad Sci U S A. 2013; 110(20):7998-8003. PMC: 3657780. DOI: 10.1073/pnas.1220817110. View

Xiao Z, Farokhzad O . Aptamer-functionalized nanoparticles for medical applications: challenges and opportunities. ACS Nano. 2012; 6(5):3670-6. PMC: 3420009. DOI: 10.1021/nn301869z. View

Xiao Z, Shangguan D, Cao Z, Fang X, Tan W . Cell-specific internalization study of an aptamer from whole cell selection. Chemistry. 2007; 14(6):1769-75. DOI: 10.1002/chem.200701330. View

Owens 3rd D, Peppas N . Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2005; 307(1):93-102. DOI: 10.1016/j.ijpharm.2005.10.010. View

Liu Y, Bhalla K, Hill C, Priest D . Evidence for involvement of tyrosine phosphorylation in taxol-induced apoptosis in a human ovarian tumor cell line. Biochem Pharmacol. 1994; 48(6):1265-72. DOI: 10.1016/0006-2952(94)90164-3. View

10.

Chan J, Rhee J, Drum C, Bronson R, Golomb G, Langer R . In vivo prevention of arterial restenosis with paclitaxel-encapsulated targeted lipid-polymeric nanoparticles. Proc Natl Acad Sci U S A. 2011; 108(48):19347-52. PMC: 3228458. DOI: 10.1073/pnas.1115945108. View

11.

Guo J, Gao X, Su L, Xia H, Gu G, Pang Z . Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials. 2011; 32(31):8010-20. DOI: 10.1016/j.biomaterials.2011.07.004. View

12.

Dhar S, Kolishetti N, Lippard S, Farokhzad O . Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci U S A. 2011; 108(5):1850-5. PMC: 3033286. DOI: 10.1073/pnas.1011379108. View

13.

Gustafson D, Merz A, Long M . Pharmacokinetics of combined doxorubicin and paclitaxel in mice. Cancer Lett. 2005; 220(2):161-9. DOI: 10.1016/j.canlet.2004.09.007. View

14.

Xiao Z, Levy-Nissenbaum E, Alexis F, Luptak A, Teply B, Chan J . Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection. ACS Nano. 2012; 6(1):696-704. PMC: 3515647. DOI: 10.1021/nn204165v. View

15.

Kim S, Jeong J, Chun K, Park T . Target-specific cellular uptake of PLGA nanoparticles coated with poly(L-lysine)-poly(ethylene glycol)-folate conjugate. Langmuir. 2005; 21(19):8852-7. DOI: 10.1021/la0502084. View

16.

Peer D, Karp J, Hong S, Farokhzad O, Margalit R, Langer R . Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2008; 2(12):751-60. DOI: 10.1038/nnano.2007.387. View

17.

Tan S, Li X, Guo Y, Zhang Z . Lipid-enveloped hybrid nanoparticles for drug delivery. Nanoscale. 2013; 5(3):860-72. DOI: 10.1039/c2nr32880a. View

18.

Aravind A, Varghese S, Veeranarayanan S, Mathew A, Nagaoka Y, Iwai S . Aptamer-labeled PLGA nanoparticles for targeting cancer cells. Cancer Nanotechnol. 2015; 3(1-6):1-12. PMC: 4452037. DOI: 10.1007/s12645-011-0024-6. View

19.

Shangguan D, Li Y, Tang Z, Cao Z, Chen H, Mallikaratchy P . Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci U S A. 2006; 103(32):11838-43. PMC: 1567664. DOI: 10.1073/pnas.0602615103. View

20.

Alexis F, Pridgen E, Molnar L, Farokhzad O . Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008; 5(4):505-15. PMC: 2663893. DOI: 10.1021/mp800051m. View